Remission-Centered Cost Relief for Psoriasis & Eczema
Clinically meaningful high-touch care relieves the burden of your highest cost members within plan year.
Key Highlights
One program, 65.5% reduction in average disease impact
Patients entered the program with substantial quality-of-life impairment. By their final assessment, average DLQI decreased by 65.5% representing a significant reduction in disease impact.
Severe disease burden fell from 51% to 12%
Despite high DLQI scores at enrollment, by their last assessment 75% improved to the mild-impact. Lower disease impact means fewer members driving escalation, non-adherence, & downstream cost.
Meaningful DLQI improvement starting 6th week, on average
By the second encounter, 35.6% of patients already achieved a clinically meaningful improvement quality of life. That increased 66.3% by final follow-up.
The clinical foundation for smarter dermatology spend
Our latest study examines what happens when eczema and psoriasis are managed continuously, not episodically. Published in Dermatology Practical & Conceptual with researchers from Brigham and Women’s Hospital and Harvard Medical School, the analysis followed 329 patients through Zest’s virtual, high-access care model. By the second encounter, 35.6% had achieved a clinically meaningful improvement in quality of life, and by final follow-up the proportion experiencing severe disease burden had fallen from 51% to 12%.
Specialty drug management is often approached primarily as a pharmacy problem. But optimizing high-cost therapy requires something health plans rarely have: ongoing visibility into the patient’s clinical status.
Zest creates the clinical infrastructure to identify who needs more care, who is doing well, and where treatment can be optimized—aligning better patient outcomes with more responsible specialty drug spend.
Let's work together
Partner with Zest Health to implement smarter, more cost-effective psoriasis and eczema care for your workforce, members, or clients. We're here to help you make a difference.
Get in touch